If you want to be truthful, ask yourself why we came out with 'Toujeo', and not just Lantus Max, or Lantus u300, as a complete rebrand and then try and force Drs to switch pts over, after restricting all Lantus samples. Remember those really sharp providers who were pissed about that? Hint: they saw right through it.
We could have just launched a u300 Lantus as a benefit to patients, if there was an actual clinical benefit outside of higher dose patients, but there wasn't. ( Lantus performed better in all 3 trials in the PI and is more potent). Basaglar was on the horizon and Sanofi was fully aware of it. They knew this event was coming and it was an attempt ( a rather successful one relatively speaking) and grabbing as much MS in basal as they could before the biosims started to appear. We all knew there would be massive MS losses at some point.
I wish everyone the best, and if I were an abl I would certainly help all of my teams network and land new gigs outside of here now!! Network, network, network, linkedin everyone you can, look outside of your comfort zone and look at med device, cgm, wound care ( most of your patients would be diabetic), nutritionals, ortho, injectibles for rheum & osteoarthritis of the knee, bracing, hospital physician liasison, etc . Think about where your years of diabetes experience would be an asset.